↓ Skip to main content

Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

Overview of attention for article published in Frontiers in Pharmacology, November 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
Published in
Frontiers in Pharmacology, November 2021
DOI 10.3389/fphar.2021.782385
Pubmed ID
Authors

Lei Wang, Lixiong Liu, Xiaoping Hong, Dongzhou Liu, Zeneng Cheng

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 17%
Student > Postgraduate 1 17%
Student > Doctoral Student 1 17%
Unknown 3 50%
Readers by discipline Count As %
Medicine and Dentistry 2 33%
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Unknown 3 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2021.
All research outputs
#15,240,835
of 22,660,862 outputs
Outputs from Frontiers in Pharmacology
#6,294
of 15,822 outputs
Outputs of similar age
#274,674
of 497,164 outputs
Outputs of similar age from Frontiers in Pharmacology
#397
of 1,123 outputs
Altmetric has tracked 22,660,862 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,822 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 497,164 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,123 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.